ClinicalTrials.gg
CompletedNCT00567255Updated Nov 21, 2014Results posted

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

A Phase 3 interventional study of Naltrexone SR 32 mg/bupropion SR 360 mg/day and Placebo in Obesity and Overweight, sponsored by Orexigen Therapeutics, Inc. Completed at 36 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-11-21.

Sponsored by Orexigen Therapeutics, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,496
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.

Enrollment
3rd of 23
1,496 · median 67
Started
2007
with 4 others
Phase 3
6 of 23
none open now
Registered
6th of 23
by date
Lead sponsor
10 of 23
Orexigen Therapeutics, Inc

Among the 23 studies testing naltrexone in Obesity, this one is the 3rd largest by enrollment, is one of 5 that started in 2007, is one of 6 in phase 3, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing naltrexone in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.

Read the detailed description

Two Phase II clinical trials demonstrated that a combination of bupropion SR and naltrexone is associated with greater weight loss than naltrexone alone, bupropion SR alone or placebo in subjects with uncomplicated obesity. The current study investigated the safety and efficacy of the combination of naltrexone SR and bupropion SR compared to placebo in obese subjects with uncomplicated obesity and in those with overweight/obesity and hypertension and/or dyslipidemia.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Obesity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male subjects aged 18 to 65 years (inclusive)
  • (weight [kg]/height [m²]) ≥30 and ≤45 kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45 kg/m² for subjects with obesity with controlled hypertension and/or dyslipidemia
  • Normotensive (systolic ≤140 mm Hg and diastolic ≤90 mm Hg). Anti-hypertensive medications were allowed with the exception of alpha-adrenergic blockers and clonidine. Medical regimen was to be stable for at least 6 weeks prior to randomization.
  • Medications for the treatment of dyslipidemia were allowed as long as the medical regimen had been stable for at least 6 weeks prior to randomization.
  • Free of opioid medication for 7 days prior to randomization
  • No abnormality of serum albumin, blood urea nitrogen (BUN), creatinine, , sodium, potassium, chloride, calcium or phosphorus
  • (ALT) and aspartate aminotransferase (AST) within 2.5 times (ULN)
  • No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC differential, or
  • Fasting glucose \<126 mg/dL and not receiving hypoglycemic agents and fasting triglycerides level \<400 mg/dL
  • No clinically significant abnormality on urinalysis
  • Thyroid stimulating hormone (TSH) within normal limits or normal triiodothyronine (T3), if TSH was below normal limits
  • Female subjects of had a negative serum pregnancy test
  • Negative urine drug screen (UDS)
  • An IDS-SR score \<2 on individual items: 5 (sadness), 6 (irritability), 7 (anxiety/tension), and 18 (suicidality) and an IDS-SR total score \<30
  • Female subjects of childbearing potential were non-lactating and agreed to continue to use effective throughout the study and 30 days after discontinuation of study drug
  • Able to comply with all required study procedures and schedule
  • Able to speak and read English
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome)
  • Serious medical condition (including but not limited to renal or hepatic insufficiency; Class III or IV congestive heart failure, history of angina pectoris, myocardial infarction, claudication, or acute limb ischemia within the previous 6 months; lifetime history of stroke)
  • History of within the previous 5 years, with exception of non-melanoma skin cancer or surgically cured cervical cancer
  • Lifetime history of serious psychiatric illness, including lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, or anorexia nervosa
  • Current serious psychiatric illness including severe personality disorder (e.g., borderline or antisocial), current severe major depressive disorder, recent (previous 6 months) suicide attempt, current active suicidal ideation or recent hospitalization due to psychiatric illness
  • Response to the bipolar disorder questions that indicated the presence of bipolar disorder
  • Required medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months prior to randomization
  • History of drug or alcohol abuse or dependence (with the exception of nicotine dependence) within 1 year prior to study initiation
  • Type I or Type II diabetes mellitus
  • Screening with a (QTc) interval (using Bazett's formula >450 millisecond (msec) [males] and >470 msec [females]) or the presence of any cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities
  • Received excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer or anticonvulsant agents or agents for the treatment of attention deficit disorder) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia (up to 2 mg lorazepam/day or equivalent dose of a benzodiazepine or hypnotic agent); any anorectic or weight loss agents; any over the-counter dietary supplements or herbs with psychoactive, appetite or weight effects; alpha-adrenergic blockers; dopamine agonists; clonidine; coumadin; theophylline; cimetidine; oral ; cholestyramine; cholestypol; Depo-Provera®; smoking cessation agents; use of opioid or opioid-like analgesics, including analgesics and antitussives
  • History of surgical or device (e.g., gastric banding) intervention for obesity
  • History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with ≥5 minutes loss of consciousness, concussion symptoms lasting ≥15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures)
  • History of treatment with bupropion or naltrexone within the preceding 12 months
  • History of or intolerance to bupropion or naltrexone
  • Initiation or discontinuation of tobacco products including inhaled tobacco (e.g., cigarettes, cigars, pipes, etc), chewing tobacco or snuff within 3 months prior to randomization or planned during study participation. Use of nicotine replacement products (e.g., nicotine gum, patch, etc) during study participation was not allowed
  • Used drugs, herbs, or dietary supplements believed to significantly affect body weight or participated in a weight loss management program within one month prior to randomization
  • Loss or gained >4.0 kilograms within the previous 3 months prior to randomization
  • Females who were pregnant or breast-feeding or planning to become pregnant during the study period or within 30 days of discontinuing study drug
  • Planned surgical procedure that could impact the conduct of the study
  • Received any drug or used an experimental device or procedure within the previous 30 days
  • Participated in any previous clinical trial conducted by Orexigen
  • Had any condition that in the opinion of the investigator made the subject unsuitable for inclusion into the study
  • Investigators, study personnel, sponsor representatives and their immediate families
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,496 participants (actual)

Study arms

  • Experimental
    NB32

    Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy

    Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day · Behavioral: Ancillary therapy

  • Placebo comparator
    Placebo

    Placebo with ancillary therapy

    Drug: Placebo · Behavioral: Ancillary therapy

Interventions

  • DrugNaltrexone SR 32 mg/bupropion SR 360 mg/day

    Drug page: Naltrexone

    Also known as: NB32

  • DrugPlacebo
  • BehavioralAncillary therapy

    Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling

06

What researchers measure

Primary outcomes

  1. Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28

    Time frame: Baseline, 28 weeks

  2. Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28

    Time frame: Baseline, 28 weeks

Secondary outcomes

  1. Body Weight- Mean Percent Change From Baseline to Week 56

    Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis. Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48).

    Time frame: Baseline, 56 weeks

  2. Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56

    Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis. Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48).

    Time frame: Baseline, 56 weeks

  3. Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28

    Time frame: Baseline, 28 weeks

  4. Change in Waist Circumference

    Time frame: Baseline, 28 weeks

  5. Change in Fasting HDL Cholesterol Levels

    Time frame: Baseline, 28 weeks

  6. Change in Fasting Triglycerides Levels, Using Log-transformed Data

    Time frame: Baseline, 28 weeks

  7. Change in IWQOL-Lite Total Scores

    IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment

    Time frame: Baseline, 28 weeks

  8. Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

    Time frame: Baseline, 28 weeks

  9. Change in Fasting Insulin Levels, Using Log-transformed Data

    Time frame: Baseline, 28 weeks

  10. Change in Fasting Blood Glucose Levels

    Time frame: Baseline, 28 weeks

  11. Change in HOMA-IR Levels, Using Log-transformed Data

    HOMA-IR= Homeostasis Model Assessment-Insulin Resistance

    Time frame: Baseline, 28 weeks

  12. Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

    Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

    Time frame: Baseline, 28 weeks

  13. Change in Fasting LDL Cholesterol Levels

    Time frame: Baseline, 28 weeks

  14. Change in Systolic Blood Pressure

    Time frame: Baseline, 28 weeks

  15. Change in Diastolic Blood Pressure

    Time frame: Baseline, 28 weeks

  16. Change in IDS-SR Total Score

    IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.

    Time frame: Baseline, 28 weeks

  17. Change in Food Craving Inventory Sweets Subscale Score

    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

    Time frame: Baseline, 28 weeks

  18. Change in Food Craving Inventory Carbohydrates Subscale Score

    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

    Time frame: Baseline, 28 weeks

07

Results

Posted Nov 21, 2014

Participant flow

Participant flow — Overall Study
MilestoneNB32Placebo
Started1001495
Completed538267
Not completed463228
Withdrew: Adverse event24168
Withdrew: Lost to follow-up7748
Withdrew: Withdrawal by subject7556
Withdrew: Lack of efficacy1933
Withdrew: Protocol violation208
Withdrew: Pregnancy60
Withdrew: Drug noncompliance,moved,other2515

Outcome measures

PrimaryCo-primary: Body Weight- Mean Percent Change From Baseline to Week 28
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · percentage of body weight
Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28
percentage of body weightNB32Placebo
Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28-6.45 ± 0.20-1.89 ± 0.26
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -4.56 · 95% CI -5.19 to -3.93
SecondaryBody Weight- Mean Percent Change From Baseline to Week 56

Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis. Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48).

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percentage of body weight
Body Weight- Mean Percent Change From Baseline to Week 56
percentage of body weightNB32Placebo
Body Weight- Mean Percent Change From Baseline to Week 56-6.40 ± 0.25-1.23 ± 0.33
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -5.16 · 95% CI -5.95 to -4.38
PrimaryCo-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28
Time frame:
Baseline, 28 weeks
Reported as:
Number · percentage of participants
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 28
percentage of participantsNB32Placebo
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 2855.64 (52.25 to 59.03)17.54 (14.05 to 21.03)
Statistical analysis
  • NB32 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.61 · 95% CI 4.95 to 8.84
SecondaryBody Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56

Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis. Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48).

Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 56
percentage of participantsNB32Placebo
Body Weight- Proportion of Subjects With ≥5% Decrease From Baseline to Week 5650.48 (46.90 to 54.07)17.11 (13.46 to 20.75)
Statistical analysis
  • NB32 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.50 · 95% CI 4.05 to 7.47
SecondaryBody Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28
Time frame:
Baseline, 28 weeks
Reported as:
Number · percentage of participants
Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 28
percentage of participantsNB32Placebo
Body Weight- Proportion of Subjects With ≥10% Decrease From Baseline to Week 2827.27 (24.23 to 30.31)7.02 (4.67 to 9.36)
Statistical analysis
  • NB32 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.36 · 95% CI 3.60 to 7.98
SecondaryChange in Waist Circumference
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · cm
Change in Waist Circumference
cmNB32Placebo
Change in Waist Circumference-6.16 ± 0.28-2.74 ± 0.38
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -3.43 · 95% CI -4.33 to -2.53
SecondaryChange in Fasting HDL Cholesterol Levels
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting HDL Cholesterol Levels
mg/dLNB32Placebo
Change in Fasting HDL Cholesterol Levels1.19 ± 0.30-1.40 ± 0.42
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 2.59 · 95% CI 1.61 to 3.57
SecondaryChange in Fasting Triglycerides Levels, Using Log-transformed Data
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · percent change
Change in Fasting Triglycerides Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in Fasting Triglycerides Levels, Using Log-transformed Data-7.32 (-9.80 to -4.76)-1.36 (-5.02 to 2.43)
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.007 · Mean difference (net): -5.96
SecondaryChange in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment

Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · units on a scale
Change in IWQOL-Lite Total Scores
units on a scaleNB32Placebo
Change in IWQOL-Lite Total Scores9.94 ± 0.416.17 ± 0.56
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 3.77 · 95% CI 2.46 to 5.09
SecondaryChange in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · percent change
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data-9.38 (-14.78 to -3.63)-1.14 (-9.11 to 7.52)
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.091 · Mean difference (net): -8.24
SecondaryChange in Fasting Insulin Levels, Using Log-transformed Data
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · percent change
Change in Fasting Insulin Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in Fasting Insulin Levels, Using Log-transformed Data-14.14 (-17.86 to -10.24)-0.50 (-6.49 to 5.88)
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -13.64
SecondaryChange in Fasting Blood Glucose Levels
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting Blood Glucose Levels
mg/dLNB32Placebo
Change in Fasting Blood Glucose Levels-2.11 ± 0.38-1.73 ± 0.52
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -0.38 · 95% CI -1.60 to 0.85
SecondaryChange in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance

Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · percent change
Change in HOMA-IR Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in HOMA-IR Levels, Using Log-transformed Data-16.44 (-20.37 to -12.31)-4.15 (-10.43 to 2.57)
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -12.29
SecondaryChange in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · units on a scale
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire
units on a scaleNB32Placebo
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire-18.32 ± 0.85-11.09 ± 1.12
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -7.23 · 95% CI -9.92 to -4.54
SecondaryChange in Fasting LDL Cholesterol Levels
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting LDL Cholesterol Levels
mg/dLNB32Placebo
Change in Fasting LDL Cholesterol Levels-4.36 ± 0.900.00 ± 1.25
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -4.36 · 95% CI -7.29 to -1.44
SecondaryChange in Systolic Blood Pressure
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · mm Hg
Change in Systolic Blood Pressure
mm HgNB32Placebo
Change in Systolic Blood Pressure-0.93 ± 0.31-1.23 ± 0.42
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 0.30 · 95% CI -0.70 to 1.30
SecondaryChange in Diastolic Blood Pressure
Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · mm Hg
Change in Diastolic Blood Pressure
mm HgNB32Placebo
Change in Diastolic Blood Pressure0.20 ± 0.22-0.67 ± 0.30
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 0.87 · 95% CI 0.16 to 1.58
SecondaryChange in IDS-SR Total Score

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.

Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · units on a scale
Change in IDS-SR Total Score
units on a scaleNB32Placebo
Change in IDS-SR Total Score-0.23 ± 0.17-0.28 ± 0.23
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 0.06 · 95% CI -0.49 to 0.60
SecondaryChange in Food Craving Inventory Sweets Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · units on a scale
Change in Food Craving Inventory Sweets Subscale Score
units on a scaleNB32Placebo
Change in Food Craving Inventory Sweets Subscale Score-3.20 ± 0.17-3.18 ± 0.22
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -0.02 · 95% CI -0.56 to 0.52
SecondaryChange in Food Craving Inventory Carbohydrates Subscale Score

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

Time frame:
Baseline, 28 weeks
Reported as:
Least squares mean · units on a scale
Change in Food Craving Inventory Carbohydrates Subscale Score
units on a scaleNB32Placebo
Change in Food Craving Inventory Carbohydrates Subscale Score-2.68 ± 0.16-2.20 ± 0.21
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -0.48 · 95% CI -0.98 to 0.02

Adverse events

Collected over Baseline, 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NB32/48—21/992 (2.1%)671/992 (67.6%)
Placebo—7/492 (1.4%)244/492 (49.6%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventNB32/48Placebo
Small intestinal obstructionGastrointestinal disorders1/9921/492
Chest painGeneral disorders0/9921/492
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9921/492
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9921/492
DizzinessNervous system disorders0/9921/492
MenorrhagiaReproductive system and breast disorders0/9921/492
Ovarian massReproductive system and breast disorders0/9921/492
Knee arthroplastySurgical and medical procedures0/9921/492
Myocardial infarctionCardiac disorders1/9920/492
PalpitationsCardiac disorders1/9920/492
Most frequent other events
Showing 10 of 13
Most frequent other events
EventNB32/48Placebo
NauseaGastrointestinal disorders290/99234/492
ConstipationGastrointestinal disorders189/99235/492
HeadacheNervous system disorders174/99243/492
Upper respiratory tract infectionInfections and infestations86/99255/492
InsomniaPsychiatric disorders97/99233/492
Dry mouthGastrointestinal disorders90/99213/492
VomitingGastrointestinal disorders84/99210/492
NasopharyngitisInfections and infestations82/99240/492
SinusitisInfections and infestations51/99235/492
DizzinessNervous system disorders68/99217/492

Baseline characteristics

All randomized subjects

Age, Continuous
Age, Continuous(years)NB32PlaceboTotal
Mean44.27 ± 11.1644.41 ± 11.3844.32 ± 11.23
Sex: Female, Male
Sex: Female, Male(Participants)NB32PlaceboTotal
Female8474201267
Male15475229
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NB32PlaceboTotal
White8354141249
Black or African American13372205
Asian12416
Native Hawaiian or Other Pacific Islander314
American Indian or Alaska Native10212
Other8210
Weight
Weight(kg)NB32PlaceboTotal
Mean100.3 ± 16.5599.21 ± 15.8699.95 ± 16.33
BMI
BMI(kg/m^2)NB32PlaceboTotal
Mean36.22 ± 4.4536.09 ± 4.2736.17 ± 4.39
08

Study locations

36 sites
  • Lovelace Scientific Resources
    Phoenix, Arizona 85016, United States
  • HOPE Research Institute
    Phoenix, Arizona 85050, United States
  • HealthStar Research
    Hot Springs, Arkansas 71913, United States
  • Northern California Research
    Carmichael, California 98608, United States
  • Sierra Medical Research
    Fresno, California 93710, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Center for Human Nutrition University of Colorado Health Sciences Center
    Denver, Colorado 80220, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • George Washington University
    Washington, District of Columbia 20037, United States
  • Suncoast Clinical Research
    Palm Harbor, Florida 34684, United States
  • Comprehensive NeuroScience, Inc
    Atlanta, Georgia 30328, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Northwest Indiana Center for Clinical Research
    Valparaiso, Indiana 46383, United States
  • Trover Center for Clinical Studies
    Madisonville, Kentucky 42431, United States
  • Nutrition and Weight Mangement Center Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Milford Emergency Associates, Inc
    Milford, Massachusetts 01757, United States
  • Summit Research Network, Inc.
    Okemos, Michigan 48864, United States
  • Twin Cities Clinical Research
    Brooklyn Center, Minnesota 55430, United States
  • Mercy Health Research
    St. Louis, Missouri 63141, United States
  • Radiant Research, Inc.
    St. Louis, Missouri 63141, United States
  • Clinical Research Center of Nevada
    Las Vegas, Nevada 89104, United States
  • Endocrinology & Diabetes Consultants
    Dover, New Hampshire 03820, United States
  • Lovelace Scientific Resources
    Albuquerque, New Mexico 87108, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Comprehensive Weight Control Program
    New York, New York 10021, United States
  • Behavioral Medical Research
    Staten Island, New York 10305, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Patient Priority
    Cincinnati, Ohio 45242, United States
  • Wells Institute For Health Awareness
    Kettering, Ohio 45429, United States
  • The Portland Clinic
    Portland, Oregon 97205, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Mountain View Clinical Research
    Greer, South Carolina 29349, United States
  • Palmetto Medical Research
    Mt. Pleasant, South Carolina 29464, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • The Cooper Institute
    Dallas, Texas 75230, United States
  • Summit Research Network, Inc.
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E; COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309. PubMed 23408728 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 5 years 5 months after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2007
First posted
Dec 4, 2007
Start
Dec 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results delay requested
Oct 30, 2012
Results first posted
Nov 21, 2014
Last update
Nov 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00567255
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
Dec 4, 2007
Start date
Dec 2007
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Nov 21, 2014
Last update
Nov 21, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion